<DOC>
	<DOC>NCT00679718</DOC>
	<brief_summary>To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.</brief_summary>
	<brief_title>A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Best corrected visual acuity of at least +0.7 ETDRS Six month history of dry eye disease Mild severity in two out of five symptoms Unanesthetized Schirmer score of less than or equal to 7mm Corneal fluorescein staining greater than or equal to 4 out of 15 or lissamine green conjunctival staining of greater than or equal to 5 out of 18 Nasal stimulated Schirmer score of less than 3mm Have ongoing ocular infection Have congenitally absent meibomian or lacrimal glands Have had punctal occlusion within a specified time prior to study Wear contact lens and refuse to remove them Have other excluded eye conditions.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>